🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →
Browsing Tag

United States Army

25 posts
Read More

Cambridge Aerospace hits $3.4bn valuation as 30,000-interceptor production target tests defence-tech scale

Cambridge Aerospace has secured $300 million at a $3.4 billion valuation as it scales Skyhammer interceptor production and develops Starhammer. The valuation has more than doubled in four months, but manufacturing 2,500 interceptors a month and converting government testing into repeat procurement will determine whether the private-market enthusiasm is justified.
Palantir Technologies has evolved from its intelligence and defence roots into a broader artificial intelligence and data software platform spanning government, manufacturing, healthcare, energy, finance and logistics. Representative image.
Read More

Palantir Technologies company profile: How AIP accelerated its rise into a $400bn AI giant

Palantir Technologies Inc. has transformed from a specialist government data-software supplier into one of the fastest-growing artificial intelligence companies in the public markets. Q2 2026 revenue surged 93%, United States commercial revenue jumped 149% and operating margins expanded sharply, but a valuation above $400 billion means investors are already paying for years of exceptional execution.
Anduril Industries is scaling Lattice defence software, autonomous aircraft, counter-drone systems and undersea vehicles as its government contract base and private valuation expand. Representative image.
Read More

Anduril Industries company profile: How Palmer Luckey and his co-founders built a $61bn AI defence challenger

Anduril Industries has grown from a defence technology start-up into a $61 billion private company spanning artificial intelligence software, autonomous aircraft, counter-drone systems, precision-strike vehicles and undersea platforms. Its $2.2 billion revenue base and expanding government contract portfolio show genuine commercial scale, but manufacturing execution and limited private-company disclosure remain critical risks.